pharmacovigilance RU

About us

A company of novel biopharmaceutical practices

  • R&D center
  • 160 mln doses
  • more than 10 countries
  • EU GMP since 2012
29 years of Petrovax

The development strategy focuses on providing patients with in-demand vaccines and biotech drugs for the prevention and treatment of infectious, orphan, and oncological diseases

products

The product portfolio includes original pharmaceutical products, contract medicines and food supplements

R&D

R&D center, patents for molecules and pharmaceutical manufacturing technologies in Russia and abroad

pharmaceutical production

Modern biotechnological production in accordance with the EAEU and EU GMP standards

export

One of the largest exporters of original pharmaceutical products and vaccines for the prevention of influenza

partnership

Partner of international Big Pharma companies: Pfizer, Abbott, Boehringer Ingelheim, ISU ABXIS

Structure of Petrovax

  • R&D-центр
    R&D-центр
  • Clinical studies and product registration
    Clinical studies and product registration
  • Pharmacovigilance
    Pharmacovigilance
  • Vaccine portfolio
    Vaccine portfolio: marketing, sales budget, medical department
  • Retail portfolio
    Retail portfolio: marketing, sales force, commerce, BI, BD, medical department, export
  • Biotech portfolio
    Biotech portfolio: BD, market access, technology transfer, marketing, medical department
  • Manufacturing
    Manufacturing
  • Quality Control
    Quality Control
  • Administration office
    Administration office

The company was founded in 1996 by a team of Russian scientists.

  • Localized full-cycle production of the immuno-oncology medicine Areima® launched in Russia.
  • Obtaining a license from the Russian Ministry of Industry and Trade to manufacture a vaccine against meningococcal infection.
  • Polyoxidonium® has been included in a new standard of medical care for adults with influenza and in new recommendations for the treatment of ARVI in children.
  • Signing a cooperation agreement with the The Union of Pediatricians of Russia to develop a culture of vaccination.
  • Signing a cooperation agreement with the Presidential Academy (RANEPA) to assess the impact of the Russian pharmaceutical industry on the country’s economic, scientific and technological development, and to strengthen pharmaceutical sovereignty.
  • Recognition at leading industry awards: Platinum Ounce (meningococcal vaccine localization project), “Partnership for Health” Award at the Man and Medicine Congress.
  • The first-ever biosimilar of a reference product for osteoporosis treatment, Forsedeno® (denosumab), has been approved in Russia.
  • Areima® (сamrelizumab) for the treatment of esophageal cancer, nasopharyngeal cancer, and lung cancer included in Russia's Essential Drug List.
  • Launch of Polyoxidonium® in a new dosage form of drop formulation.
  • Polyoxidonium® has been included in the Clinical Guidelines of the Ministry of Health of Russia for acute respiratory viral infections treatment (ARVI).
  • Signing of a Cooperation agreement with the Government of the Moscow Region to implement Russia’s first full-cycle manufacturing project for a vaccine against meningococcal infection.
  • Signing of a Cooperation agreement with Sechenov University to conduct research on biopharmaceuticals for rare and oncological diseases, as well as vaccines against high-consequence infectious diseases.
  • Signing of a Memorandum of strategic cooperation with the N.F. Gamaleya NRCEM to enable collaborative scientific research in cancer-related issues and to investigate the potential of the combination therapy of mRNA-based biotechnological medications with camrelizumab (Areima®).
  • Recognition at leading industry awards: Platinum Ounce (Areima®), SmartPharma Awards (Polyoxidonium® and Uronext®), the Man and Medicine Congress Award and Vedomosti Impulse Award.
  • In partnership with the N.F. Gamaleya NRCEM, successfully completed a technology transfer project for the full-cycle production of Fabagal® (agalsidase beta), from API biosynthesis to the finished dosage form.
  • Authorization in Russia of the original drug Areima® (camrelizumab) for the treatment of nasopharyngeal and esophageal cancer.
  • Launch of new products: the antibacterial drug Reflamaid® (fosfomycin) for the treatment of urinary tract infections, and a new line of dietary supplements Venarel® to support women’s health.
  • Signing of a Memorandum of Understanding with the Interdisciplinary Society of Specialists in Hepatic Tumors (ISSHT) to improve cancer diagnosis, prevention, and treatment.
  • Signing of a Memorandum with the Russian Society of Clinical Oncology (RUSSCO) aimed at improving the diagnosis, prevention, and treatment of cancer in Russia, as well as development of innovative pharmaceutical products and technologies.
  • 15-year anniversary of Petrovax manufacturing complex in Moscow Region: full cycle manufacture — the synthesis of APIs, the production of sterile and non-sterile medicines, EU and EAEU GMP.
  • The rare Fabry disease treatment Fabagal has received the market approval . First deliveries of the drug.
  • Launch of new products: Demefecil, Omegika®, Sundevit®, Vitaferr® Express.
  • Polyoxidonium® was included in the updated Temporary Anti-COVID-19 Guidelines of the Russian Ministry of Health and in the Clinical Guidelines of the Russian Ministry of Health on the Influenza Prevention and Treatment in Adults.
  • Extension of therapeutic indications for the quadrivalent influenza vaccine Grippol® Quadrivalent: the vaccine is now approved for use in children from 6 months.
  • Market launch of new products: Uronext®, VitaFerr®,Gialera®, ARTNEO®.
  • Obtaining USA, Indian, South Korean and EU patents for Longidaza®.
  • Production expansion: opening of the 4th line of production for manufacturing of injectable dosage forms, start of construction of new biotechnological complex.
  • The beginning of cooperation with ISU ABXIS (South Korea) to localize production of medicine for orphan therapy — Fabry disease.
  • Сhange in the composition of shareholders — Interros Group left the membership of the company.
  • Large-scale clinical trials program for Polyoxidonium® and Longidaza® in the prevention and treatment of COVID-19.
  • Project for the development and manufacture of the vaccine against COVID-19 — Convidecia — in cooperation with CanSino Biologics Inc.
  • Start of supplies of Grippol® Quadrivalent, Russian first quadrivalent inactivated subunit adjuvanted influenza vaccine.
  • Market launch of Velson® (INN: Melatonin).
  • Registration of a new dosage form — Polyoxidonium® solution.
  • Commissioning of the 3rd manufacturing line for the APIs and finished dosage forms.
  • Successful completion of a post-registration study (PASS) of Polyoxidonium® in Europe.
  • Localized in Russia Prevenar® 13 vaccine supplies for the National Immunization Schedule.
  • Market launch of Imoferaza® cosmetic cream.
  • Beginning of cooperation with Boehringer Ingelheim to localize full-cycle production of thrombolytic medicines Metalyse® and Actilyse®.
  • Joining the Interros Group.
  • Opening of the 2nd line for the production of vials and ampoules.
  • Start of a localization project of Prevenar® 13 pneumococcal vaccine manufacturing in cooperation with Pfizer.
  • Obtaining EU GMP certificates, export of Polyoxidonium® to the EU.
  • Start of export of Grippol® plus vaccine.
  • Market launch of Longidaza®.
  • Opening of a manufacturing and warehouse complex in Moscow Region. The first syringe line for vaccine production in Russia.
  • Market launch of the first Russian influenza vaccine Grippol® plus, supplies for the National Immunization Schedule.
  • Development and production of vaccines against pandemic strain of influenza A/H1N1: 15 million doses.
  • Company foundation.
  • Registration of Polyoxidonium® medicine and Grippol® vaccine.
  • Opening of the production facilities for manufacture of APIs, soft and solid dosage forms.
  • The beginning of the partnership with Solvay Pharma (currently, Abbott) for the construction of a pharmaceutical complex for the development and production of immunobiological medicines, including Grippol® plus vaccine.
vision

Leading pharmaceutical innovations

mission

Expanding access to cutting-edge therapies

values
  • Openness
  • Responsibility
  • Proactivity
  • Teamwork
pdf Company presentation (PDF 5,79 МB)
pdf Company booklet (PDF 18 MB)

This site contains information for medical and pharmaceutical professionals.

To view the content, please, confirm that you have the appropriate qualifications.